Open Access

Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer

  • Authors:
    • Sarayut Lucien Geater
    • Pichitpon Chaniad
    • Keson Trakunram
    • Warangkana Keeratichananont
    • Suhaimee Buya
    • Paramee Thongsuksai
    • Pritsana Raungrut
  • View Affiliations

  • Published online on: November 11, 2021     https://doi.org/10.3892/ol.2021.13130
  • Article Number: 12
  • Copyright: © Geater et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have reported the diagnostic and prognostic value of serum microRNA (miR)‑145 and vascular endothelial growth factor (VEGF) levels in various types of cancer; however, their clinical use in non‑small cell lung cancer (NSCLC) remains unclear. The present study included 215 patients, 106 with NSCLC and 109 with other lung diseases (OLDs). miR‑145 expression levels were determined using reverse transcription‑quantitative PCR (RT‑qPCR) and VEGF levels were measured using an ELISA. The diagnostic performance was assessed using a receiver operating characteristic curve and area under the curve (AUC) analysis. A Kaplan‑Meier survival curve and Cox regression analysis were employed to evaluate the prognostic significance of the markers. The biological function of miR‑145 was examined in A549 and H1792 cell lines. The effects of miR‑145 on cell proliferation of NSCLC cells were evaluated by flow cytometry, and the expression levels of miR‑145 and cell cycle‑related genes were determined by RT‑qPCR. The results revealed that miR‑145 and VEGF exhibited fair diagnostic performance [AUC, 0.61 (95% CI, 0.55‑0.68) and AUC, 0.64 (95% CI, 0.57‑0.71), respectively]. Combining age and smoking status with miR‑145 and VEGF provided the best model for differentiating patients with NSCLC from those with OLDs (AUC, 0.76; 95% CI, 0.69‑0.83). Furthermore, low serum miR‑145 levels were associated with poor overall survival [hazard ratio (HR), 0.48; 95% CI, 0.27‑0.85], whereas high VEGF levels were not associated with poor overall survival (HR, 1.47; 95% CI, 0.81‑2.68). In addition, the results of the in vitro experiments indicated that miR‑145 decreased cell proliferation via the induction of cell cycle arrest. In conclusion, the findings of the present study suggested that combining miR‑145 and VEGF levels with clinical risk factors may be a potential diagnostic scheme for NSCLC. In addition, serum miR‑145 may be used as a prognostic marker. These results indicated that miR‑145 may function as a tumor suppressor in NSCLC.
View Figures
View References

Related Articles

Journal Cover

January-2022
Volume 23 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Geater SL, Chaniad P, Trakunram K, Keeratichananont W, Buya S, Thongsuksai P and Raungrut P: Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer. Oncol Lett 23: 12, 2022
APA
Geater, S.L., Chaniad, P., Trakunram, K., Keeratichananont, W., Buya, S., Thongsuksai, P., & Raungrut, P. (2022). Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer. Oncology Letters, 23, 12. https://doi.org/10.3892/ol.2021.13130
MLA
Geater, S. L., Chaniad, P., Trakunram, K., Keeratichananont, W., Buya, S., Thongsuksai, P., Raungrut, P."Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer". Oncology Letters 23.1 (2022): 12.
Chicago
Geater, S. L., Chaniad, P., Trakunram, K., Keeratichananont, W., Buya, S., Thongsuksai, P., Raungrut, P."Diagnostic and prognostic value of serum miR‑145 and vascular endothelial growth factor in non‑small cell lung cancer". Oncology Letters 23, no. 1 (2022): 12. https://doi.org/10.3892/ol.2021.13130